These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 2182912

  • 21. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
    Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D.
    Virology; 2000 Feb 01; 267(1):8-16. PubMed ID: 10648178
    [Abstract] [Full Text] [Related]

  • 22. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
    Khattar SK, Manoharan V, Bhattarai B, LaBranche CC, Montefiori DC, Samal SK.
    mBio; 2015 Jul 21; 6(4):e01005. PubMed ID: 26199332
    [Abstract] [Full Text] [Related]

  • 23. Identification, cloning, and sequencing of a fragment of Amsacta moorei entomopoxvirus DNA containing the spheroidin gene and three vaccinia virus-related open reading frames.
    Hall RL, Moyer RW.
    J Virol; 1991 Dec 21; 65(12):6516-27. PubMed ID: 1942245
    [Abstract] [Full Text] [Related]

  • 24. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.
    Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, Corey L.
    Lancet; 1991 Mar 09; 337(8741):567-72. PubMed ID: 1671940
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Use of persistent infections with vaccinia virus recombinants to introduce alterations in foreign proteins: an application to HIV-1 env protein.
    Esteban M, Ramón Rodríguez J, Jimenez V, Rodríguez D.
    Virus Res; 1996 Dec 09; 46(1-2):45-56. PubMed ID: 9029776
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M.
    J Virol; 2017 May 01; 91(9):. PubMed ID: 28179536
    [Abstract] [Full Text] [Related]

  • 29. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.
    Luo L, Li Y, Cannon PM, Kim S, Kang CY.
    Proc Natl Acad Sci U S A; 1992 Nov 01; 89(21):10527-31. PubMed ID: 1438241
    [Abstract] [Full Text] [Related]

  • 30. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    Gherardi MM, Nájera JL, Pérez-Jiménez E, Guerra S, García-Sastre A, Esteban M.
    J Virol; 2003 Jun 01; 77(12):7048-57. PubMed ID: 12768024
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants.
    Chanda PK, Natuk RJ, Mason BB, Bhat BM, Greenberg L, Dheer SK, Molnar-Kimber KL, Mizutani S, Lubeck MD, Davis AR.
    Virology; 1990 Apr 01; 175(2):535-47. PubMed ID: 2183470
    [Abstract] [Full Text] [Related]

  • 34. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
    Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B, Alam SM, Scearce RM, Sutherland LL, Yu JS, Decker JM, Shaw GM, Montefiori DC, Korber BT, Hahn BH, Haynes BF.
    J Virol; 2005 Jan 01; 79(2):1154-63. PubMed ID: 15613343
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
    Hu SL, Klaniecki J, Dykers T, Sridhar P, Travis BM.
    AIDS Res Hum Retroviruses; 1991 Jul 01; 7(7):615-20. PubMed ID: 1768463
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.